{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-287650","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.832362+00:00","generated_at":"2026-05-16T18:27:05.053985+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common","bullets":["Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.","Note Amendment No. 2 extends maturity of $6.22M secured promissory note to April 1, 2026.","Exchange of 25 Series M Preferred shares for 361,271 common shares; issued unregistered under Section 3(a)(9)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-287650","json":"https://secwatch.observer/filing/0001193125-25-287650.json","markdown":"https://secwatch.observer/filing/0001193125-25-287650.md","text":"https://secwatch.observer/filing/0001193125-25-287650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525287650/0001193125-25-287650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525287650/jagx-20251117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:27:05.053985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"125beaedb1346efa6a20090e77480f2045429d25","claim":"Jaguar Health, Inc. amended debt with Iliad Research and Trading, L.P..","evidence_excerpt":"On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525287650/0001193125-25-287650-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Counterparty","value":"Iliad Research and Trading, L.P."},{"label":"Event","value":"amendment"}]},{"claim_id":"6ac7c90bb0babdc5c74bac86daff85bf5299b379","claim":"Jaguar Health, Inc. amended loan with Streeterville Capital, LLC maturing April 1, 2026.","evidence_excerpt":"On November 17, 2025, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “Note Amendment No. 2”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date (as amended, the “Note Purchase Agreement”). Pursuant to the Note Amendment No. 2, the maturity date of the Note is extended to April 1, 2026.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525287650/0001193125-25-287650-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Maturity","value":"April 1, 2026"},{"label":"Event","value":"amendment"}]},{"claim_id":"ae05f64b660feca0ee550faefc25ee0bdfd32cf4","claim":"Jaguar Health, Inc. amended debt with Streeterville Capital, LLC.","evidence_excerpt":"On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525287650/0001193125-25-287650-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Event","value":"amendment"}]},{"claim_id":"f1bbbc5f6e9169206e828d9d6b49740a651c33ef","claim":"Jaguar Health, Inc. amended debt with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC).","evidence_excerpt":"On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525287650/0001193125-25-287650-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Counterparty","value":"Uptown Capital, LLC (f/k/a Irving Park Capital, LLC)"},{"label":"Event","value":"amendment"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}